The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals
Abstract
BACKGROUND: Efavirenz is a commonly used antiretroviral drug that causes neurologic side effects in more than 50% of patients. OBJECTIVE: To characterize efavirenz-associated neurologic symptoms in a randomized, controlled study of initial antiretroviral treatment. DESIGN: Substudy of a randomized, double-blind, controlled trial of combination antiretroviral regimens (A5095) that was performed between March 2001 and January 2002. SETTING: Multicenter academic clinical trial units. PARTICIPANTS: HIV-infected patients who were initiating therapy in the context of a controlled trial. MEASUREMENTS: Neuropsychological performance measures, including the Digit Symbol Substitution Test and the Trail Making Test (Parts A and B); symptom questionnaires; standardized assessments of sleep quality, anxiety, and depression; and efavirenz plasma concentrations. RESULTS: Twenty of 303 (6.6%) enrolled participants prematurely discontinued the study. Neuropsychological performance improved in both groups over time without significant differences between patients who were receiving efavirenz and those who were not. The efavirenz group experienced more neurologic symptoms at week 1 (P < 0.001) but not at weeks 4, 12, or 24. A sleep index revealed that participants receiving efavirenz had more "bad dreams" during the first week of therapy (P = 0.038). No significant changes in anxiety or depressed mood were noted. Changes in efavirenz-associated neurologic symptoms were correlated to efavirenz plasma concentrations at week 1 but not at later time points. Twelve (6%) patients receiving efavirenz stopped taking the drug before the end of the study because of central nervous system symptoms. LIMITATIONS: Participant selection may have been biased in favor of patients with fewer psychiatric complications. The study design permitted substitution of a new drug in place of efavirenz in cases of treatment-limiting toxicity. CONCLUSIONS: In a large controlled trial, efavirenz use was associated with neurologic symptoms distinct from depression and anxiety that began early in therapy but resolved by week 4. Improvement in neuropsychological performance was comparable in patients who were receiving efavirenz and those who were not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Nonparametrics: Statistical Methods Based on Ranks
Mergenthaler, M. J., & Lehmann, E. L. (1979) · Technometrics · doi:10.2307/1268531 · Cited by 3,329
Neuropsychological Assessment, 2nd Ed
Fisher, J. M. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198502000-00014 · Cited by 1,583
WAIS-R manual : Wechsler adult intelligence scale-revised
Wechsler, D. (1981) · Medical Entomology and Zoology · Cited by 1,559
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Self-citationMarzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., & Buclin, T. (2001) · AIDS · doi:10.1097/00002030-200101050-00011 · Cited by 840
Halstead-Reitan Neuropsychological Test Battery
(2012) · SpringerReference · doi:10.1007/springerreference_180120 · Cited by 749
Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R., Gulick, R. M., Clifford, D. B., Hulgan, T., Marzolini, C., & Acosta, E. P. (2004) · PubMed · Cited by 627
Self-citationStatistical Methods for the Analysis of Repeated Measurements
Davis, C. S. (2002) · Springer Texts in Statistics · doi:10.1007/b97287 · Cited by 577
Cited by
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia
Simioni, S., Cavassini, M., Annoni, J.-M., Rimbault Abraham, A., Bourquin, I., Schiffer, V., Calmy, A., Chave, J.-P., Giacobini, E., Hirschel, B., et al. (2010) · AIDS · doi:10.1097/qad.0b013e3283354a7b · Cited by 702
HIV-associated neurocognitive disorder
Clifford, D. B., & Ances, B. M. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70269-x · Cited by 670
Self-citationGrinsztejn, B., Hosseinipour, M. C., Ribaudo, H. J., Swindells, S., Eron, J., Chen, Y. Q., Wang, L., Ou, S.-S., Anderson, M., McCauley, M., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70692-3 · Cited by 494
Self-citationDolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
The NAMSAL ANRS 12313 Study Group (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904340 · Cited by 326
HIV and Depression – a systematic review of interventions
Sherr, L., Clucas, C., Harding, R., Sibley, E., & Catalan, J. (2011) · Psychology, Health & Medicine · doi:10.1080/13548506.2011.579990 · Cited by 325
Metadata
- Authors
- Clifford, D. B., Evans, S., Yang, Y., Acosta, E. P., Goodkin, K., Tashima, K., Simpson, D., Dorfman, D., Ribaudo, H., Gulick, R. M., & for the A5097s Study Team*
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2005-11-15
- Volume
- 143
- Issue
- 10
- Pages
- 714-721
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2011912864
- Cited by
- 270
- References
- 22
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. https://app.cochat.ai/papers/10.7326/0003-4819-143-10-200511150-00008
- The paper
- Clifford, D. B., Evans, S., Yang, Y., Acosta, E. P., Goodkin, K., Tashima, K., Simpson, D., Dorfman, D., Ribaudo, H., Gulick, R. M., & for the A5097s Study Team*. (2005). Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-143-10-200511150-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.